KIRKLAND, Wash. – Sunlight.com, a leading telehealth platform expanding access to personalized metabolic health and weight management care, released the findings of its Peptide Gray Market Report, revealing a fast-growing population of U.S. adults buying injectable peptides outside the regulated pharmacy system. While GLP-1 weight-loss drugs like Ozempic have dominated peptide coverage, the survey of 1,000 U.S. peptide users finds that the broad…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.